<DOC>
	<DOCNO>NCT00522886</DOCNO>
	<brief_summary>To determine MTD toxicity standard dose cetuximab together concurrent individualize , isotoxic accelerate radiotherapy cisplatin-vinorelbine</brief_summary>
	<brief_title>Phase I Cetuximab Concurrent Radio-chemotherapy</brief_title>
	<detailed_description>Phase I trial escalate dos vinorelbine standard dos radiotherapy , cisplatin cetuximab . Eligible patient receive 2 cycle carboplatin ( AUC 5 ) day 1 gemcitabine ( 1250 mg/m2 ) day 1,8 . One cycle duration 21 day . Patients without progressive disease ( PD ) accord RECIST criterion ( appendix 1 ) enter phase I dose-escalation part study . Chest radiation give concurrently cetuximab , cisplatin vinorelbine . The latter drug escalate three step dose-limiting toxicity occur . On day 43 , i.e . 14 day last gemcitabine delivery , radiotherapy start . Radiotherapy : In patient every dose-step , radiation give follow : first 3 week : 1.5 Gy BID dose 45 Gy 30 fraction , 2 Gy QD mean lung dose ( MLD , relate radiation-induced lung damage ) 19 Gy . Maximum dose : 69 Gy give 5.5 week . Maximum dose spinal cord : 50 Gy . Cetuximab : All patient receive start dose 400 mg/ m2 7 day begin radiotherapy ( i.e . day 36 ) , thereafter weekly dose 250 mg/ m2 course radiotherapy 5 consecutive week . Cetuximab deliver day chemotherapy . Cisplatin : In patient every dose-step , cisplatin give follow : Step 1 , 2 3 : 50 mg/ m2 day 43 , 50 ; 40 mg/m2 day 64 . Vinorelbine escalate three step : Step 1 : 10 mg/ m2 day 43 , 50 ; 8 mg/m2 day 66 73 . Step 2 : 20 mg/ m2 day 43 , 50 ; 8 mg/m2 day 66 73 . Step 3 : 20 mg/ m2 day 43 , 50 ; 15 mg/m2 day 66 73 .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirm nonsmall cell lung cancer Inoperable stage III ( UICC 2002 ; sixth edition ) ( pleural effusion ) WHO performance status 0 1 Less 10 % weight loss last 6 month Lung function : FEV1 least 50 % DLCO least 50 % predict value No recent severe cardiac disease Adequate bone marrow function Adequate renal function Adequate hepatic function Life expectancy 6 month Measurable cancer Willing able comply study prescription 18 year old Not pregnant breast feed Written inform consent No previous radiotherapy chest Not nonsmall cell lung cancer histology Mixed pathology History prior chest radiotherapy Recent ( &lt; 3 month ) myocardial infarction Uncontrolled infectious disease Less 18 year old Inadequate pulmonary function Other active malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>cetuximab</keyword>
	<keyword>concurrent</keyword>
	<keyword>iso-toxic</keyword>
	<keyword>NSCLC</keyword>
</DOC>